Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure

References

• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. 2000. The protein data bank. Nucleic Acids Res. 28:235–242.
   PubMed Web of Science ®Google Scholar
• Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, et al. 1999. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 274:6718–6725.
   PubMed Web of Science ®Google Scholar
• Chen B, Greenside P, Paik H, Sirota M, Hadley D, Butte AJ. 2015. Relating chemical structure to cellular response: an integrative analysis of gene expression, bioactivity, and structural data across 11,000 compounds. CPT Pharmacometrics Syst Pharmacol. 4:576–584.
   PubMedGoogle Scholar
• Das SK, Chakrabarti R. 2006. Role of PPAR in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 1:193–209.
   PubMedGoogle Scholar
• Dey D, Medicherla S, Neogi P, Gowri M, Cheng J, Gross C, Sharma SD, Reaven GM, Nag B. 2003. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metab Clin Exp. 52:1012–1018.
   PubMed Web of Science ®Google Scholar
• Ehara N, Ono K, Morimoto T, Kawamura T, Abe M, Hasegawa K. 2004. The possible role of peroxisome proliferator-activated receptor gamma in heart failure. Exp Clin Cardiol. 9:169–173.
   PubMedGoogle Scholar
• Gong H, Yuan Z, Zhan L. 2016 . High-throughput screening against ∼6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery. Mol Divers. 20:537–549.
   PubMed Web of Science ®Google Scholar
• Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 18:2714–2723.
   PubMed Web of Science ®Google Scholar
• Harvey AL, Edrada-Ebel R, Quinn RJ. 2015. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 14:111–129.
   PubMed Web of Science ®Google Scholar
• Heusser SA, Howard RJ, Borghese CM, Cullins MA, Broemstrup T, Lee US, Lindahl E, Carlsson J, Harris RA. 2013. Functional validation of virtual screening for novel agents with general anesthetic action at ligand-gated ion channels. Mol Pharmacol. 84:670–678.
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK. 2005 . ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model. 45:177–182.
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, Cao Y. 2009. Automated docking screens: a feasibility study. J Med Chem. 52:5712–5720.
   PubMed Web of Science ®Google Scholar
• Jolliffe IT, Cadima J. 2016. Principal component analysis: a review and recent developments. Philos Trans A Math Phys Eng Sci. 374:20150202.
   PubMed Web of Science ®Google Scholar
• Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. 2008. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and Beagle dogs. J Pharmacol Sci. 108:40–48.
   PubMed Web of Science ®Google Scholar
• Kasznicki J, Drzewoski J. 2014. Heart failure in the diabetic population: pathophysiology, diagnosis and management. Arch Med Sci. 10:546–556.
   PubMed Web of Science ®Google Scholar
• Lee SK, Chang GS, Lee IH. 2004. The PreADME: PC-based program for batch predication of ADME properties. EuroQSAR. 9:5–10.
   Google Scholar
• Lewis SN, Garcia Z, Hontecillas R, Bassaganya-Riera J, Bevan DR. 2015. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands. J Comput Aided Mol Des. 29:421–439.
   PubMed Web of Science ®Google Scholar
• Nikolova N, Jaworska J. 2003. Approaches to measure chemical similarity: a review. QSAR Comb Sci. 22:1006–1026.
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004 . UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 25:1605–1612.
   PubMed Web of Science ®Google Scholar
• Sarma S. 2012. Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?. Curr Mol Pharmacol. 5:255–263.
   PubMedGoogle Scholar
• Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U. 2006. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension. 47:586–589.
   PubMed Web of Science ®Google Scholar
• Shoichet BK, Kuntz ID. 1993. Matching chemistry and shape in molecular docking. Protein Eng. 6:723–732.
   PubMedGoogle Scholar
• Shoichet BK, Leach AR, Kuntz ID. 1999. Ligand solvation in molecular docking. Proteins. 34:4–16.
   PubMed Web of Science ®Google Scholar
• Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, Saito T, Masuda Y. 2000. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 87:596–602.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. 2011. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2:236–240.
   PubMedGoogle Scholar
• Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, et al. 2014. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 92:73–89.
   PubMed Web of Science ®Google Scholar
• Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. 1996. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 39:665–668.
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. 2000. The PPARs: from orphan receptors to drug discovery. J Med Chem. 43:527–550.
   PubMed Web of Science ®Google Scholar
• Wojtkowska I, Tysarowski A, Seliga K, Siedlecki JA, Juraszyński Z, Marona M, Greszata L, Skrobisz A, Kaminski K, Sawicki R, et al. 2014. PPAR gamma expression levels during development of heart failure in patients with coronary artery disease after coronary artery bypass-grafting. PPAR Res. 2014:242790.
   PubMed Web of Science ®Google Scholar
• Yu X, Geer LY, Han L, Bryant SH. 2015. Target enhanced 2D similarity search by using explicit biological activity annotations and profiles. J Cheminform. 7:55.
   PubMed Web of Science ®Google Scholar
• Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, et al. 2001. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 98:13919–13924.
   PubMed Web of Science ®Google Scholar